Pacira BioSciences (NASDAQ:PCRX) Stock, Quote.Headers.trade-ideas

Pacira BioSciences

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.

PCRX

Analyst Color

Biotech

Equities

News

Downgrades

Health Care

Price Target

Legal

Analyst Ratings

Movers

Trading Ideas

General

Pacira BioSciences faces a significant setback as the U.S. District Court invalidates its key patent on Exparel, leading to a 40% stock drop. Exparel, crucial to Pacira&#39;s revenue, is now vulnerable, prompting a downgrade from JP Morgan with a new price target of $10.

Pain Management-Focused Pacira BioSciences Loses Patent Fight For Key Drug, JP Morgan Analyst Downgrades On Unclear Path

JetBlue

Pre-Market Outlook

Markets

AILE

FTRE

JBLU

MARA

RILY

JetBlue Airways, B. Riley Financial, Hawaiian Electric And Other Big Stocks Moving Lower In Monday&#39;s Pre-Market Session

Healthcare

Long Ideas

CSTL

SAVA

Top 5 Health Care Stocks That May Explode In July

Pacira BioSciences Inc

Truist Securities analyst Les Sulewski downgrades Pacira BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>) from Buy to Sell and lowers the price target from $30 to $8.

Truist Securities Downgrades Pacira BioSciences to Sell, Lowers Price Target to $8

Friday,&nbsp;Pacira BioSciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>) announced that the U.S. District Court for the District of New Jersey found that the company&#8217;s U.S. Patent No. 11,033,495 (the ‘495 patent) <a target="_blank" href="https://www.benzinga.com/pressreleases/24/08/g40293827/pacira-biosciences-comments-on-ruling-on-exparel-patent-litigation-from-u-s-district-court-for-the" rel="noreferrer noopener">is not valid</a>.
&#8220;We remain steadfast in our belief in the strength and validity of our intellectual property and that eVenus is infringing upon our patents,&#8221; said Frank D. Lee, chief executive officer of Pacira BioSciences. &#8220;In light of the Court&#8217;s decision, we are considering our legal options, which include pursuing an appellate review at the U.S. Court of Appeals for the Federal Court as warranted.&#8221;
In November 2021, Pacira BioSciences <a target="_blank" href="https://investor.pacira.com/news-releases/news-release-details/pacira-files-lawsuit-against-evenus-patent-infringement" rel="noreferrer noopener">filed</a> a lawsuit in the United States District Court for the District of New Jersey against eVenus Pharmaceutical Laboratories, Inc. for patent infringement of U.S. Patent Number 11,033,495.
The '495 patent is related to Exparel&nbsp;(bupivacaine liposome injectable suspension) and expires on January 22, 2041.
Exparel is Pacira BioSciences&#8217; non-opioid analgesic pain management and is indicated for postsurgical analgesia.
The complaint sought an injunction to prevent the infringing manufacture, use, and sale of a potential generic product described in an Abbreviated New Drug Application that eVenus filed with the FDA in August 2021.
JP Morgan &#8220;previewed that an unfavorable ruling for Pacira was the most likely outcome, but this ruling is clearly the worst-case scenario&#8230;&#8221; The stock fell more than 40% on Friday after the ruling.
Exparel accounts for almost 80% of Pacira BioSciences&#8217; revenues, which can be eroded due to a lack of patents.
In the second quarter, Exparel sales reached $136.9 million, <a target="_blank" href="https://www.benzinga.com/pressreleases/24/07/g40049670/pacira-biosciences-reports-second-quarter-2024-financial-results" rel="noreferrer noopener">versus $135.1 million a year ago</a>, of the total sales of $178.0 million.
Contracted discounts and vial mix offset the second quarter volume growth of 3%.
&#8220;It is also the main source of growth as the company&#8217;s other two assets are relatively immaterial, and the Street doesn&#8217;t ascribe much value to the company&#8217;s R&amp;D pipeline,&#8221; JP Morgan commented on Exparel.
Amid the lack of a clear path to recovery for Pacira BioSciences shares, JP Morgan has downgraded to Underweight from Overweight, with a price target of $10, reduced from the <a target="_blank" href="https://www.benzinga.com/quote/PCRX/analyst-ratings" rel="noreferrer noopener">prior price target of $45</a>.
Price Action: PCRX stock is up 5.13% at $12.30&nbsp;at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/08/40319861/noninvasive-treatment-provider-neuronetics-agrees-to-merge-with-canadian-firm-greenbrook-tms-report" target="_blank" rel="noreferrer noopener">Noninvasive Treatment Provider Neuronetics Agrees To Merge With Canadian Firm Greenbrook TMS; Reports Q2 Earnings And Guidance Below Expectations</a>.</li>
</ul>

In the latest quarter, 12 analysts provided ratings for Pacira BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>), showcasing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $33.25, a high estimate of $57.00, and a low estimate of $10.00. A decline of 25.15% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2024/1723485647_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The perception of Pacira BioSciences by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$14.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Oren Livnat</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$39.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>Serge Belanger</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$22.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Hardik Parikh</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$10.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Gary Nachman</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$37.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$37.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Serge Belanger</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$43.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Les Sulewski</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$30.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>David Amsellem</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$42.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Balaji Prasad</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$25.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Serge Belanger</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$43.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Oren Livnat</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$57.00</td>
<td>$57.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Pacira BioSciences. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Pacira BioSciences compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
To gain a panoramic view of Pacira BioSciences's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/PCRX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Pacira BioSciences analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Get to Know Pacira BioSciences Better</h2>
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.
<h3>Pacira BioSciences: Financial Performance Dissected</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Pacira BioSciences displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 5.05%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Pacira BioSciences's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 10.61% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Pacira BioSciences's ROE excels beyond industry benchmarks, reaching 2.13%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.17%, the company showcases effective utilization of assets.
Debt Management: With a below-average debt-to-equity ratio of 0.74, Pacira BioSciences adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: Simplified</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Where Pacira BioSciences Stands With Analysts

RBC Capital analyst Gregory Renza downgrades Pacira BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>) from Outperform to Sector Perform and lowers the price target from $37 to $14.

RBC Capital Downgrades Pacira BioSciences to Sector Perform, Lowers Price Target to $14

U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 50 points on Monday.
Shares of JetBlue Airways Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBLU#NASDAQ">JBLU</a>) fell sharply in today's pre-market trading after the company announced a $400 million convertible senior notes offering.
JetBlue Airways shares dipped 5.6% to $5.71 in pre-market trading.
Here are some big stocks recording losses in today's pre-market trading session.
<ul>
<li>iLearningEngines, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AILE#NASDAQ">AILE</a>) shares declined 25.8% to $4.29 in pre-market trading. ILearningEngines will report financial results for the second quarter before the opening bell on Tuesday, Aug. 13.</li>
<li>B. Riley Financial, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RILY#NASDAQ">RILY</a>) fell 25% to $12.70 in pre-market trading after the company reported preliminary second-quarter financial results.</li>
<li>Hawaiian Electric Industries, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HE#NYSE">HE</a>) dipped 7.7% to $14.28 pre-market trading after the company reported weak second-quarter earnings.</li>
<li>Fortrea Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTRE#NASDAQ">FTRE</a>) fell 6.5% to $23.53 in pre-market trading after the company posted downbeat second-quarter results and lowered its FY24 revenue guidance.  </li>
<li>Pagaya Technologies Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGY#NASDAQ">PGY</a>) shares declined 6% to $13.37 in pre-market trading. The company reported second-quarter results on Friday.</li>
<li>Pacira BioSciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>) fell 4.4% to $11.18 in pre-market trading. JP Morgan analyst Hardik Parikh downgraded Pacira BioSciences from Overweight to Underweight and lowered the price target from $45 to $10.</li>
<li>Marathon Digital Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MARA#NASDAQ">MARA</a>) fell 3.5% to $16.44 as the company announced a proposed private offering of $250 million of convertible senior notes.</li>
</ul>
Now Read This: &lt;a href=&#8221;https://www.benzinga.com/trading-ideas/long-ideas/24/04/38311966/izea-worldwide-and-2-other-stocks-under-3-insiders-are-buying&#8221;&gt;&lt;em&gt; IZEA Worldwide And 2 Other Stocks Under $3 Insiders Are Buying &lt;/em&gt;&lt;/a&gt;

JetBlue Airways, B. Riley Financial, Hawaiian Electric And Other Big Stocks Moving Lower In Monday's Pre-Market Session

HC Wainwright &amp; Co. analyst Oren Livnat maintains Pacira BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>) with a Buy and lowers the price target from $57 to $39.

HC Wainwright & Co. Maintains Buy on Pacira BioSciences, Lowers Price Target to $39

Needham analyst Serge Belanger maintains Pacira BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>) with a Buy and lowers the price target from $43 to $22.

Needham Maintains Buy on Pacira BioSciences, Lowers Price Target to $22

JP Morgan analyst Hardik Parikh downgrades Pacira BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>) from Overweight to Underweight and lowers the price target from $45 to $10.

JP Morgan Downgrades Pacira BioSciences to Underweight, Lowers Price Target to $10

Pacira BioSciences Shares Resume Trading, Then Again Halt On Circuit Breaker, Shares Down -47.7%

Pacira BioSciences Shares Halted On Circuit Breaker To The Downside, Stock Now Down -39.6%

Pacira BioSciences Shares Resume Trade

WIIM

Pacira BioSciences shares are trading lower after the  U.S. District Court for the District of New Jersey found that Patent No. 11,033,495 is not valid. CEO Frank D. Lee stated that the company is considering its legal options, including pursuing an appellate review at the U.S. Court of Appeals for the Federal Circuit if warranted.

Pacira BioSciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced that the U.S. District Court for the District of New Jersey has found that the company's U.S. Patent No. 11,033,495 (the ‘495 patent) is not valid. &nbsp;
"We remain steadfast in our belief in the strength and validity of our intellectual property and that eVenus is infringing upon our patents," said Frank D. Lee, chief executive officer of Pacira BioSciences. "In light of the Court's decision, we are considering our legal options, which include pursuing an appellate review at the U.S. Court of Appeals for the Federal Court as warranted."
"We firmly believe we have built a strong portfolio of intellectual property and that the EXPAREL franchise is well protected on multiple levels. Three separate infringement suits are underway, and we have additional patents that are forthcoming," added Mr. Lee.

Management

Pacira BioSciences Announces The U.S. District Court For The District Of New Jersey Has Found That Patent No. 11,033,495 Is Not Valid; CEO Frank D. Lee Says "In Light Of The Court's Decision, We Are Considering Our Legal Options, Which Include Pursuing An Appellate Review At The U.s. Court Of Appeals For The Federal Court As Warranted."

Pacira BioSciences Shares Halted On Circuit Breaker To The Downside, Stock Now Down -12.6%

Raymond James analyst Gary Nachman maintains Pacira BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>) with a Outperform and lowers the price target from $41 to $37.

Raymond James Maintains Outperform on Pacira BioSciences, Lowers Price Target to $37

RBC Capital analyst Gregory Renza maintains Pacira BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>) with a Outperform and lowers the price target from $42 to $37.

RBC Capital Maintains Outperform on Pacira BioSciences, Lowers Price Target to $37

Pacira BioSciences shares are trading higher after the company reported better-than-expected Q2 financial results.

Needham analyst Serge Belanger reiterates Pacira BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>) with a Buy and maintains $43 price target.

Reiteration

Needham Reiterates Buy on Pacira BioSciences, Maintains $43 Price Target

Guidance

Pacira BioSciences Reiterates Full-year 2024 Financial Guidance Total Revenue Of $680M - $705M, Est $694.66M

Pacira Pharmaceuticals (PCRX – Research Report) received a Hold rating and price target from Raymond James analyst Gary Nachman today. The company'...

Raymond James downgrades Pacira Pharmaceuticals (PCRX) to a Hold

Piper Sandler analyst David Amsellem downgraded the rating on Pacira Pharmaceuticals (PCRX – Research Report) to a Hold yesterday, setting a price ...

Pacira Pharmaceuticals Faces Uncertain Future Amidst Patent Litigation and Rising Competition: A Hold Rating Justified

Analyst Serge Belanger from Needham maintained a Buy rating on Pacira Pharmaceuticals (PCRX – Research Report) and decreased the price target to $2...

Maintaining a Buy: Navigating Exparel's Patent Challenges and Long-Term Growth

In a report released today, Oren Livnat from H.C. Wainwright reiterated a Buy rating on Pacira Pharmaceuticals (PCRX – Research Report), with a pri...

Pacira Pharmaceuticals: Strong Patent Portfolio Defends Against Generics, Undervalued Market Position Prompts Buy Rating

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Pacira Pharmaceuticals (PCRX – Research Report), Iov...

Analysts Are Bullish on Top Healthcare Stocks: Pacira Pharmaceuticals (PCRX), Iovance Biotherapeutics (IOVA)

Truist Financial analyst Les Sulewski maintained a Buy rating on Pacira Pharmaceuticals (PCRX – Research Report) today. The company's shares closed...

Truist Financial Sticks to Its Buy Rating for Pacira Pharmaceuticals (PCRX)

The 1-Minute Market Report August 10, 2024

Pacira downgraded by J.P. Morgan, Piper, RBC, Raymond James

In a report released today, Balaji Prasad from Barclays assigned a Hold rating to Pacira Pharmaceuticals (PCRX – Research Report), with a price tar...

Pacira Pharmaceuticals (PCRX) Gets a Hold from Barclays

Organon downgraded, Amneal upgraded as J.P. Morgan reviews specialty pharma

ACTV

AFMC

AFSM

AMPH

AMRX

APPS

ARKF

ARKK

AVUV

AXON

BAPR

BITO

BOTZ

CIBR

COPX

DOCS

EGHT

EMQQ

FTNT

IOVA

IRWD

IVOO

IVOV

LUMN

MAGS

MSOS

NTLA

PAYO

PRGO

SIVR

SPLV

SPMD

SPMO

SPMV

SPSM

SPUS

SPUU

SPVM

SPVU

SPWR

SPXE

SPXL

SPXN

SPXS

SPXT

SPXU

SPXV

SPYD

SPYG

SPYV

SPYX

SQEW

SQLV

SSLY

SSPY

SVAL

SYLD

TEVA

TMDV

TPHD

TPLC

TPSC

TTEC

UAUG

UJAN

UMAR

UMAY

UOCT

UPRO

USMC

USMF

USVM

VSAT

VSCO

VTRS

XPEL

Earnings

Press Releases

Pacira BioSciences Reports First Quarter 2024 Financial Results and Announces $150 Million Share Repurchase program

Pacira BioSciences, Inc. Announces Proposed Offering of $250.0 Million Aggregate Principal Amount of Convertible Senior Notes

Pacira BioSciences, Inc. Announces Pricing of $250.0 Million Aggregate Principal Amount of 2.125% Convertible Senior Notes due 2029

enGene Announces the Election of Paul Hastings and Wouter Joustra to its Board of Directors

Pacira BioSciences to Participate in Fireside Chat at the 2024 Jefferies Global Healthcare Conference

Centers for Medicare and Medicaid Propose New Reimbursement for EXPAREL in All Outpatient Surgical Environments Beginning January 1, 2025

Pacira to Report Second Quarter 2024 Financial Results on Tuesday July 30, 2024

Pacira BioSciences Reports Second Quarter 2024 Financial Results

Pacira BioSciences Comments on Ruling on EXPAREL Patent Litigation from U.S. District Court for the District of New Jersey

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Pacira BioSciences

Pacira BioSciences (PCRX) Forecast

Pacira BioSciences (NASDAQ:PCRX) Stock, Quote.Headers.trade-ideas